Technical Analysis for XTLB - XTL Biopharmaceuticals Ltd.

Grade Last Price % Change Price Change
grade C 2.3115 -5.65% -0.14
XTLB closed down 5.65 percent on Monday, March 18, 2019, on 74 percent of normal volume. It was able to find support at its 50 day moving average.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical XTLB trend table...

Date Alert Name Type % Chg
Mar 18 Fell Below 20 DMA Bearish 0.00%
Mar 18 50 DMA Support Bullish 0.00%
Mar 18 Gapped Down Weakness 0.00%
Mar 15 Crossed Above 20 DMA Bullish -5.65%
Mar 15 Narrow Range Bar Range Contraction -5.65%
Mar 15 Gapped Up Strength -5.65%
Mar 13 Fell Below 20 DMA Bearish -4.09%
Mar 13 Narrow Range Bar Range Contraction -4.09%
Mar 13 Earnings Movers Other -4.09%
Mar 13 Gapped Down Weakness -4.09%

Older signals for XTLB ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Track My Stocks
Configure default chart indicators
Basic chart:

Profile
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of clinical unmet needs. It is focused on late stage clinical development of drugs for the treatment of multiple myeloma, schizophrenia, and hepatitis C. The company's lead drug candidate is recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma blood cancer, as well as for the treatment of severe anemia. The rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma blood cancer. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials as a therapy for psychotic diseases, with focus on schizophrenia. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Herzliya, Israel.
Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Natural Sciences Medication Pharmaceutical Products Pharmacy Schizophrenia Multiple Myeloma FDA Hepatitis C
Is XTLB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Mar 5 56 Stocks Moving In Tuesday's Mid-Day Session
Jan 22 ARNC, RNN, EDIT and SDLP among notable midday movers
Jan 4 Biotechs lead broad market advance, XBI up 5%
Dec 26 Microcaps mostly among midday movers
Dec 26 EyePoint Pharmaceuticals and Sesen Bio among healthcare gainers; ZIOPHARM Oncology and Agenus among losers
Nov 21 Consolidated Research: 2018 Summary Expectations for Discovery, Focus Financial Partners, Art's-Way Manufacturing Co., Digital Ally, US Gold, and XTL Biopharmaceuticals — Fundamental Analysis, Key Performance Indications
Nov 13 70 Biggest Movers From Yesterday
Nov 1 XTL Biopharmaceuticals reports 9M results
Nov 1 XTL Biopharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Update
Oct 15 Midday Gainers / Losers (10/15/2018)
See more XTLB news...
Indicators
Indicator Value
52 Week High 3.94
52 Week Low 1.43
Average Volume 5,146
200-Day Moving Average 2.1101
50-Day Moving Average 2.2507
20-Day Moving Average 2.3922
10-Day Moving Average 2.3436
Average True Range 0.1607
ADX 9.68
+DI 24.2585
-DI 30.551
Chandelier Exit (Long, 3 ATRs ) 2.2679
Chandelier Exit (Short, 3 ATRs ) 2.6321
Upper Bollinger Band 2.6182
Lower Bollinger Band 2.1662
Percent B (%b) 0.32
BandWidth 18.894741
MACD Line 0.0114
MACD Signal Line 0.0212
MACD Histogram -0.0098
Fundamentals Value
Market Cap 11.93 Million
Num Shares 5.16 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -2.10
Price-to-Sales 0.00
Price-to-Book 5.40
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.58
Resistance 3 (R3) 2.58 2.49 2.54
Resistance 2 (R2) 2.49 2.42 2.49 2.52
Resistance 1 (R1) 2.40 2.38 2.36 2.40 2.51
Pivot Point 2.31 2.31 2.29 2.31 2.31
Support 1 (S1) 2.22 2.24 2.18 2.22 2.12
Support 2 (S2) 2.13 2.20 2.13 2.10
Support 3 (S3) 2.04 2.13 2.09
Support 4 (S4) 2.04